Literature DB >> 27162160

Combining high dose external beam radiotherapy with a simultaneous integrated boost to the dominant intraprostatic lesion: Analysis of genito-urinary and rectal toxicity.

Nora Sundahl1, Gert De Meerleer1, Geert Villeirs2, Piet Ost1, Wilfried De Neve1, Nicolaas Lumen3, Pieter De Visschere2, Marc Van Eijkeren1, Valérie Fonteyne4.   

Abstract

BACKGROUND AND
PURPOSE: Local recurrences after radiotherapy are dose-dependent and occur in the dominant intraprostatic lesion (DIL). The purpose of this study was to evaluate the impact of a simultaneous integrated boost (SIB) to the magnetic resonance imaging (MRI)-defined DIL on toxicity.
MATERIALS AND METHODS: Four-hundred and ten patients were treated with intensity-modulated radiotherapy. A median dose of 78Gy was prescribed to the prostate. A SIB of 82Gy to the DIL was performed in 225 patients (SIB+). Genitourinary and rectal toxicity on fixed time points up to 8years were compared between SIB- (185 patients) and SIB+ patients. Chi-square, Fisher's exact and Kaplan-Meier statistics were applied. With a median follow up of 72months, the six-year actuarial risk of genitourinary and rectal toxicity grade⩾2 was 31% and 12% respectively. The actuarial risk of developing toxicity and incidence of symptoms at fixed time points were not increased with a SIB.
CONCLUSION: Performing a SIB did not increase genitourinary or rectal toxicity up to 8years' follow-up.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Dose escalation; Intraprostatic lesion; Prostate cancer; Toxicity

Mesh:

Year:  2016        PMID: 27162160     DOI: 10.1016/j.radonc.2016.04.031

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  6 in total

1.  Intensity-modulated radiotherapy of prostate cancer with simultaneous integrated boost after molecular imaging with 18F-choline-PET/CT : Clinical results and quality of life.

Authors:  Marsha Schlenter; Vanessa Berneking; Barabara Krenkel; Felix M Mottaghy; Thomas-Alexander Vögeli; Michael J Eble; Michael Pinkawa
Journal:  Strahlenther Onkol       Date:  2018-03-06       Impact factor: 3.621

2.  MRI-guided focal boost to dominant intraprostatic lesion using volumetric modulated arc therapy in prostate cancer. Results of a phase II trial.

Authors:  Almudena Zapatero; Maria Roch; Pablo Castro Tejero; David Büchser; Carmen Martin de Vidales; Saturnino González; Pablo Rodríguez; Luis Alberto San Jose; Guillermo Celada; Maria Teresa Murillo
Journal:  Br J Radiol       Date:  2021-09-19       Impact factor: 3.039

3.  Value of 18F-fluorocholine PET/CT in predicting response to radical radiotherapy in patients with localized prostate cancer.

Authors:  Matteo Sepulcri; Marco Fusella; Lea Cuppari; Alessandra Zorz; Marta Paiusco; Laura Evangelista
Journal:  Clin Transl Radiat Oncol       Date:  2021-07-27

4.  Prognostic Value of Pretreatment MRI in Patients With Prostate Cancer Treated With Radiation Therapy: A Systematic Review and Meta-Analysis.

Authors:  Sungmin Woo; Sangwon Han; Tae-Hyung Kim; Chong Hyun Suh; Antonio C Westphalen; Hedvig Hricak; Michael J Zelefsky; Hebert Alberto Vargas
Journal:  AJR Am J Roentgenol       Date:  2019-12-04       Impact factor: 3.959

Review 5.  Prostate irradiation with focal dose escalation to the intraprostatic dominant nodule: a systematic review.

Authors:  Thomas Feutren; Fernanda G Herrera
Journal:  Prostate Int       Date:  2018-03-27

6.  Validation of T2- and diffusion-weighted magnetic resonance imaging for mapping intra-prostatic tumour prior to focal boost dose-escalation using intensity-modulated radiotherapy (IMRT).

Authors:  E J Alexander; J R Murray; V A Morgan; S L Giles; S F Riches; S Hazell; K Thomas; S A Sohaib; A Thompson; A Gao; D P Dearnaley; N M DeSouza
Journal:  Radiother Oncol       Date:  2019-09-05       Impact factor: 6.280

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.